Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Major Interest In Shares

15 Feb 2008 09:05

Oxford Biomedica PLC15 February 2008 For Immediate Release 15 February 2008 Oxford Biomedica Plc TR-1: Notifications of Major Interests in Shares Oxford Biomedica Plc 1. Identity of the issuer or the underlyingissuer of existing shares to which votingrights are attached: 2. Reason for notification (yes/no) Yes An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may resultin the acquisition of shares already issued to which voting rightsare attached An event changing the breakdown of voting rights Other (please specify): Cubana Investments Limited 3. Full name of person(s) subject tonotification obligation: 4. Full name of shareholder(s) (ifdifferent from 3): 5. Date of transaction (and date on 12 February 2008which the threshold is crossed orreached if different): 6. Date on which issuer notified: 14 February 2008 7. Threshold(s) that is/are crossed or 5%reached: 8: Notified Details A: Voting rights attached to shares Class/type of Situation previous to Resulting situation after the triggeringshares the triggering transaction transactionIf possibleuse ISIN code Number of Number of Number of Number of voting Percentage of shares voting shares rights voting rights rights Direct Indirect Direct Indirect GB0006648157 - - 30,597,220 30,597,220 5.70% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration date Exercise/ No. of voting Percentage offinancial conversion period/ rights that may be voting rightsinstrument date acquired (if the instrument exercised/ converted) Total (A+B) Number of voting rights Percentage of voting rights 30,597,220 5.70% 9. Chain of controlled undertakings through which the voting rights and /orthe financial instruments are effectively held, if applicable: Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxyholder will cease to hold: 12. Date on which proxy holder willcease to hold voting rights: 13. Additional information: 14 Contact name: Andrew Wood 15. Contact telephone number: 01865 783000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Sep 20179:25 amRNSTotal Voting Rights
30th Aug 20174:34 pmRNSCTL019 receives FDA approval
29th Aug 20177:00 amRNSStuart Paynter starts as new CFO
24th Aug 201710:41 amRNSHardman Research: Ready for CTL019 approval
23rd Aug 201710:31 amRNSDirector Dealings / Market Share Purchase
22nd Aug 201710:35 amRNSDirector Dealings / Market Share Sale and Purchase
17th Aug 20177:00 amRNSInterim Results
11th Aug 20177:00 amRNSOXB announces Innovate UK £2m collaboration
7th Aug 20179:05 amRNSHolding(s) in Company
7th Aug 20177:00 amRNSMHRA Licence For Commercial Supply
1st Aug 20179:19 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSNotice of Interim Results
24th Jul 201710:10 amRNSDirector Dealings / Market Share Purchase
18th Jul 20178:47 amRNSDirector Dealings / Market Share Sale and Purchase
14th Jul 20174:49 pmRNSDirector/PDMR Shareholding
14th Jul 20173:30 pmRNSPDMR Shareholding
14th Jul 201711:41 amRNSLTIP for Long Term Incentive Plan
13th Jul 201712:38 pmRNSDirector Dealings / Market Share Sale and Purchase
13th Jul 20177:15 amRNSHoldings in Company
13th Jul 20177:00 amRNSFDA AdCom Recommends CTL019 for Approval
11th Jul 20179:29 amRNSDirector Dealings / Market Share Sale and Purchase
7th Jul 201710:15 amRNSHardman Research: Major deal to supply Novartis
6th Jul 20177:15 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSMajor Commercial and Clinical Supply Agreement
3rd Jul 20172:20 pmRNSTotal Voting Rights
3rd Jul 20172:18 pmRNSBlock Listing
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.